S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis. [electronic resource]
Producer: 20140505Description: 1420-7 p. digitalISSN:- 1532-1827
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Aryl Hydrocarbon Hydroxylases -- genetics
- Camptothecin -- administration & dosage
- Colorectal Neoplasms -- drug therapy
- Cytochrome P-450 CYP2A6
- Drug Combinations
- Female
- Glucuronosyltransferase -- genetics
- Humans
- Irinotecan
- Male
- Middle Aged
- Neoplasm Metastasis
- Organoplatinum Compounds -- administration & dosage
- Oxaliplatin
- Oxonic Acid -- administration & dosage
- Pharmacogenetics
- Polymorphism, Genetic
- Tegafur -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.